Outcomes
death, intracerebral hematoma, vein thrombosis/pulmonary embolism, neurological deterioration, hematoma
THROMBOEMBOLIC EVENT, MYOCARDIAL INFARCTION, INTRACEREBRAL HEMATOMA, CEREBELLAR HEMORRHAGE, ISCHEMIC STROKE, INTRAVENTRICULAR HEMORRHAGE, SECONDARY, HEMATOMA, CLINICAL SYNDROMES
The primary outcome was the presence of HE on follow-up imaging at 24 (±3) hours, defined as intracerebral hematoma volume increase by at least 33% or 6 mL from baseline, in accordance with prior research.Prespecified secondary outcomes were symptomatic HE, defined as HE with neurological deterioration (worsening of NIHSS score by at least 4 points or GCS score by at least 2 points) or death within 7 days; absolute hematoma volume change by 24±3 hours; ordinal mRS score, mRS score 0 to 4, and mRS score 0 to 3 at 90 days; in-hospital death; death within 90 days; major thromboembolic events (ischemic stroke, myocardial infarction, or deep vein thrombosis/pulmonary embolism defined as clinical syndromes with supporting paraclinical evidence) within 90 days; and neurosurgical intervention up to day 2.Prespecified subgroups were onset-to-treatment time (≤6 versus >6 hours), baseline hematoma volume (≤30 versus >30 mL), hematoma location (originally categorized into deep, lobar, and cerebellar but modified to a dichotomous analysis of nonlobar versus lobar due to small number of participants with cerebellar hemorrhage), intraventricular hemorrhage (absent versus present), GCS (≤12 versus >12), age (originally with a cutoff of 70 years but modified to ≤80 versus >80 years due to small number of participants aged ≤70 years), and spot sign (absent versus present).